Autopsy report · NCT05425862

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

“Enrolment suspended to further assess supplementary non-clinical study data.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Suspended: paused, and may or may not restart.
• 48 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

Peter MacCallum Cancer Centre, Australia

Sponsor type

University, hospital or other

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

Pidnarulex; Talazoparib

Participants

48 (planned, not actual)

Sites

5

Countries

Australia

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.